Dr. Antonarakis received his medical degree from the University of Wales College of Medicine and completed his residency at Johns Hopkins Hospital. Board-certified in Medical Oncology and Internal Medicine, he has published over 250 peer-reviewed articles that have significantly advanced the understanding of prostate cancer biology and treatment resistance. His research has identified key androgen receptor splice variants that drive resistance to hormonal therapies, leading to the development of new therapeutic approaches. Dr. Antonarakis has been honored with awards from ASCO, AACR, and the Prostate Cancer Foundation for his innovative contributions to cancer research and patient care. He is also dedicated to education, mentoring medical students and oncology fellows at MSKCC.
Dr. Emmanuel S. Antonarakis is a leading expert in the molecular mechanisms of prostate cancer resistance to therapy. At MSKCC, he focuses on integrating molecular diagnostics into clinical practice to personalize treatment strategies for patients with advanced prostate cancer. Dr. Antonarakis is actively involved in groundbreaking clinical trials exploring novel hormonal therapies and biomarkers that predict treatment response, aiming to overcome drug resistance and improve patient survival rates.
Dr. Antonarakis received his medical degree from the University of Wales College of Medicine and completed his residency at Johns Hopkins Hospital. Board-certified in Medical Oncology and Internal Medicine, he has published over 250 peer-reviewed articles that have significantly advanced the understanding of prostate cancer biology and treatment resistance. His research has identified key androgen receptor splice variants that drive resistance to hormonal therapies, leading to the development of new therapeutic approaches. Dr. Antonarakis has been honored with awards from ASCO, AACR, and the Prostate Cancer Foundation for his innovative contributions to cancer research and patient care. He is also dedicated to education, mentoring medical students and oncology fellows at MSKCC.